SIASUN(SZ:300024) 3 6 Ke·2025-11-04 00:01Core Insights - Agile Medical recently completed a Series B financing round of several hundred million RMB, led by Mingxi Capital, with participation from Yuanhe Holdings, Licheng Investment, and Nantong Investment Management, along with existing investors Qianji Capital and Yuanhe Origin [1] - The funding will primarily be used for global commercialization expansion, iterative development of surgical robot products, and upgrades to advanced technology platforms [1] Group 1 - The core product AGIBOT® laparoscopic surgical robot received market approval in March 2025 and has completed over a hundred complex clinical applications in top-tier hospitals [1] - The AGIBOT® robot features an integrated suspension design and a dual-guidance system combining laser and camera visualization, reducing average docking time to under 3 minutes [1][2] - The surgical platform includes a force-sensing module and dual-motor drive, allowing healthcare personnel to maneuver the cart with one hand, enhancing flexibility in crowded operating rooms [1] Group 2 - The development of surgical robots is guided by clinical needs, but challenges exist in the integration of medical and engineering practices [1] - The robot's design enhances the flexibility and control precision of instruments during complex laparoscopic surgeries, providing over 96 liters of effective operational space [2] - Agile Medical has established a research and production base in Suzhou, capable of producing 100 systems and 20,000 surgical instruments annually, focusing on cost control and supply chain management for competitive advantage [2] Group 3 - The company aims to enhance capabilities in force feedback and artificial intelligence to improve the robot's perception and decision-making abilities, facilitating intelligent upgrades [2] - Agile Medical has initiated overseas certification processes and is engaging with potential clinical partners in various international markets to prepare for global expansion [2]